Cargando…

Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects

In this analysis, we examined the relationship between progression-free survival (PFS) and mutation status of 18 homologous recombination repair (HRR) genes in patients in the non-germline BRCA-mutated (non-gBRCAm) cohort of the ENGOT-OV16/NOVA trial (NCT01847274), which evaluated niraparib maintena...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mirza, Mansoor Raza, Lindahl, Gabriel, Mahner, Sven, Redondo, Andrés, Fabbro, Michel, Rimel, Bobbie J., Herrstedt, Jørn, Oza, Amit M., Canzler, Ulrich, Berek, Jonathan S., González-Martín, Antonio, Follana, Phillipe, Lord, Rosemary, Azodi, Masoud, Estenson, Kasey, Wang, Zebin, Li, Yong, Gupta, Divya, Matulonis, Ursula, Feng, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035404/ https://www.ncbi.nlm.nih.gov/pubmed/36970052 http://dx.doi.org/10.1158/2767-9764.CRC-22-0240

Ejemplares similares

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
por: del Campo, Josep M., et al.
Publicado: (2019)

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
por: Matulonis, Ursula A., et al.
Publicado: (2019)

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
por: O’Cearbhaill, Roisin E., et al.
Publicado: (2022)

Safety and management of niraparib monotherapy in ovarian cancer clinical trials
por: Monk, Bradley J, et al.
Publicado: (2023)

Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial
por: Callens, Celine, et al.
Publicado: (2023)

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
por: Monk, Bradley J., et al.
Publicado: (2020)

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer
por: Lorusso, Domenica, et al.
Publicado: (2022)

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
por: Monk, Bradley J., et al.
Publicado: (2022)

Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial
por: Fujiwara, Keiichi, et al.
Publicado: (2021)

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial
por: Pujade-Lauraine, Eric, et al.
Publicado: (2023)

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2023)

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
por: Grisham, Rachel N., et al.
Publicado: (2023)

Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions
por: Herzog, Thomas J, et al.
Publicado: (2023)

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
por: Moore, Kathleen N., et al.
Publicado: (2021)

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
por: Monk, Bradley J, et al.
Publicado: (2021)

Niraparib for ovarian cancer
Publicado: (2021)

Ov2 is a modulator of OvHV-2 RTA mediated gene expression
por: Dry, Inga, et al.
Publicado: (2019)

Nouveau coronavirus (NcOV)
por: Bricaire, François
Publicado: (2013)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)
por: Banerjee, Susana, et al.
Publicado: (2021)

Evaluation of glycoprotein Ov8 as a potential antigen for an OvHV-2-specific diagnostic assay
por: Alhajri, Salim M., et al.
Publicado: (2018)

Deletion of gene OV132 attenuates Orf virus more effectively than gene OV112
por: Yamada, Yumiko, et al.
Publicado: (2022)

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
por: Wang, Zebin, et al.
Publicado: (2019)

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
por: Sun, Kaiming, et al.
Publicado: (2018)

Tandem Use of OvMANE1 and Ov-16 ELISA Tests Increases the Sensitivity for the Diagnosis of Human Onchocerciasis
por: Shintouo, Cabirou Mounchili, et al.
Publicado: (2021)

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
por: Colombo, N., et al.
Publicado: (2023)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

The NR3B subgroup: an ovERRview
por: Tremblay, Annie M., et al.
Publicado: (2007)

The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice
por: Hess, Jessica A., et al.
Publicado: (2016)

Classical novae
por: Bode, Michael F, et al.
Publicado: (2008)

Nova and Glance
por: Rodrigues Moreira, Belmiro
Publicado: (2013)

Super nova
por: Shorter, Wayne
Publicado: (1988)

Nova express
por: Burroughs, William S., 1914-1997
Publicado: (1977)

Vita nova /
por: Dante Alighieri, 1265-1321
Publicado: (1947)

Cosmologia nova
por: Chechelnitsky, Albert M
Publicado: (2008)

Novae news
Publicado: (2012)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Regulation of Ov2 by virus encoded microRNAs
por: Nightingale, Katie, et al.
Publicado: (2019)

Discovery of an Inhibitor of Z-Alpha1 Antitrypsin Polymerization
por: Berthelier, Valerie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ee23dor18bvsv2e6bmd5171n7l